Omri Amirav-Drory
Omri Amirav-Drory17Omri Amirav-Drory
General Partner, Board Member and Board Observer
Rate
About
Frequently asked
What is Omri Amirav-Drory's current role?
Omri Amirav-Drory is currently General Partner, Board Member and Board Observer.
Comments
No comments yet. Be the first to share your take.
Profile
About Omri Amirav-Drory
Omri Amirav-Drory is General Partner, Board Member and Board Observer. Omri is a board member of C2i Genomics, Eleven Therapeutics, EdiTy Therapeutics, Wild Biotech, Mana.bio, and Pangea Biomed and part of the team at NFX. This profile tracks their companies, funding activity, and news mentions across the AI ecosystem.
Board member of
- C2i GenomicsComprehensive whole-genome monitoring for cancer recurrence and progression.
- Eleven TherapeuticsIsraeli-UK biotech company developing novel RNA therapeutics for rare genetic diseases.
- EdiTy TherapeuticsDeveloping a novel immune cell-based delivery platform for intracellular therapeutic protein transfer.
- Wild BiotechTherapeutics company developing novel treatments for complex diseases.
- Mana.bioAI-powered platform for developing lipid nanoparticles for oligonucleotide therapies.
- Pangea BiomedBiotech company using AI and deep RNA analysis to predict cancer treatment response.